This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rzonca SO et al. (2004) Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145: 401–406
Kahn SE et al. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427–2443
Takeda Pharmaceuticals letter to healthcare providers [www.fda.gov/medwatch/safety/2007/Actosmar0807.pdf] (accessed 4 May 2007).
Schwartz AV et al. (2006) Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91: 3349–3354
Hangartner TN and Johnston CC (1990) Influence of fat on bone measurements with dual-energy absorptiometry. Bone Miner 9: 71–81
Acknowledgements
The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
AV Schwartz is a consultant for GlaxoSmithKline. SR Cummings declared he has no competing interests.
Rights and permissions
About this article
Cite this article
Schwartz, A., Cummings, S. Does rosiglitazone adversely affect bone formation and bone mineral density in postmenopausal women?. Nat Rev Endocrinol 3, 622–623 (2007). https://doi.org/10.1038/ncpendmet0562
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet0562